Condition
Metastatic Olfactory Neuroblastoma
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Recruiting1
Not Yet Recruiting1
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06176989Phase 2Recruiting
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
NCT07527169Phase 2Not Yet RecruitingPrimary
A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma
NCT06308575Phase 2WithdrawnPrimary
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
Showing all 3 trials